TrialBosnian journal of basic medical sciences2008

Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB/ IV non-small cell lung cancer.

Bakir Mehić et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.